title: Salicylate promotes myeloperoxidase-initiated LDL oxidation: antagonization by its metabolite gentisic acid.
abstract: The oxidative modification of low density lipoprotein (LDL) may play a significant role in atherogenesis. Tyrosyl radicals generated by myeloperoxidase (MPO) can act as prooxidants of LDL oxidation. Taking into consideration, that monophenolic compounds are able to form phenoxyl radicals in presence of peroxidases, we have tested salicylate, in its ability to act as a prooxidant in the MPO system. Measurement of conjugated dienes and lipid hydroperoxides were taken as indicators of lipid oxidation. Exposure of LDL preparations to MPO in presence of salicylate revealed that the drug could act as a catalyst of lipid oxidation in LDL. The radical scavenger ascorbic acid as well as heme poisons (cyanide, azide) and catalase were inhibitory. The main metabolite of salicylic acid, gentisic acid, showed inhibitory action in the MPO system. Even when lipid oxidation was maximally stimulated by salicylate the LDL oxidation was efficaciously counteracted in presence of gentisic acid at salicylate/gentisic acid ratios that could be reached in plasma of patients receiving aspirin medication. Gentisic acid was also able to impair the tyrosyl radical catalyzed LDL peroxidation. The results suggest that salicylate could act like tyrosine via a phenoxyl radical as a catalyst of LDL oxidative modification by MPO. But the prooxidant activity of this radical species is effectively counteracted by the salicylate metabolite gentisic acid.
authors.affiliation: Institute of Molecular Genetics, University of Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Hermann
authors.forename: S
authors.initials: S
authors.lastname: Kapiotis
authors.forename: R
authors.initials: R
authors.lastname: Hofbauer
authors.forename: C
authors.initials: C
authors.lastname: Seelos
authors.forename: I
authors.initials: I
authors.lastname: Held
authors.forename: B
authors.initials: B
authors.lastname: Gmeiner
mesh_terms: D001161:Arteriosclerosis / Q000209:etiology; D001241:Aspirin / Q000378:metabolism / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D005609:Free Radicals / Q000378:metabolism; D005841:Gentisates; D006801:Humans; D062385:Hydroxybenzoates / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D015227:Lipid Peroxidation / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000737:chemistry* / Q000378:metabolism*; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D016877:Oxidants / Q000737:chemistry / Q000378:metabolism; D010084:Oxidation-Reduction; D009195:Peroxidase / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D010636:Phenols / Q000378:metabolism; D020156:Salicylic Acid / Q000378:metabolism / Q000494:pharmacology*; D014443:Tyrosine / Q000378:metabolism
chemical_list: D016166:Free Radical Scavengers; D005609:Free Radicals; D005841:Gentisates; D062385:Hydroxybenzoates; D008077:Lipoproteins, LDL; D016877:Oxidants; D010636:Phenols; C042329:phenoxy radical; D014443:Tyrosine; D009195:Peroxidase; D020156:Salicylic Acid; D001241:Aspirin; C010925:2,5-dihydroxybenzoic acid